Fatty Acids · Supplement Engine
Omega-3 Fatty Acids
(EPA/DHA)
Fish oil, algal oil, and the difference between
a powerful tool and expensive false hope
HIGH TG lowering · MODERATE depression, recovery · LOW CVD all-comers
Summary: Fish oil is one of the most-purchased supplements in the world, but most people taking it for heart protection are wasting their money — three massive trials found zero benefit in general populations. The genuine benefits are real but specific: it reliably lowers triglycerides at the right
That's the general answer. Your stack is different.
Check your whole stackFish oil, algal oil, and the difference between
a powerful tool and expensive false hope
HIGH TG lowering · MODERATE depression, recovery · LOW CVD all-comers
§5 — The Evidence
| Claimed Benefit | Evidence | Verdict |
|---|---|---|
|
Triglyceride lowering
STRONG
What would change this: A large RCT showing no TG reduction at 2-4g/day with carefully characterized formulations. |
Dose-dependent; clinically meaningful at 2-4g/day. AHRQ review; multiple meta-analyses. | Works — if dosed correctly |
|
Hard CVD event reduction (all-comers)
WEAK
What would change this: Definitive 3-arm RCT (EPA-only vs EPA+DHA vs inert placebo, ≥4g/day, 5-year event-driven, 15,000+ participants). |
REDUCE-IT (N=8,179), STRENGTH (N=13,078), ASCEND (N=15,480). EPA-only 4g/day: 25% RRR in high-risk. EPA+DHA: neutral. | Conditional — OTC fish oil does NOT protect most hearts |
|
Depression / mood
MODERATE
What would change this: Large RCT showing EPA-dominant formula fails to separate from inert placebo vs mineral oil control. |
SMD = -1.03 (p=0.03) — formulation-specific. Liao et al. 2019 meta-analysis (N=2,160). DHA-dominant formulas fail. | Works — only with ≥60% EPA at 1-2g/day |
|
Anti-inflammatory (CRP/IL-6)
MODERATE
What would change this: Well-powered RCT finding no cytokine reduction at ≥2-3g/day in elevated-CRP population. |
Linear cytokine reduction at ≥2-3g/day. Multiple RCTs. Effect primarily in elevated-inflammation populations. | Works at higher doses in elevated inflammation |
|
Athletic recovery (DOMS)
MODERATE
What would change this: ISSN position stand reversal or meta-analysis showing no DOMS benefit at 1-6g/day. |
ISSN 2025 Position Stand (Jäger et al.) — Tier 1 evidence. Reduced soreness; improved RBC deformability. | Works — backed by Tier 1 evidence |
|
Cognitive decline prevention
WEAK
What would change this: 10+ year prevention trial starting before neurological decline onset, showing significant benefit. |
DHA membrane incorporation mechanistically sound; RCTs in established decline mostly null. DATA UNAVAILABLE for minimum effective dose. | Unproven in established decline |
|
Algal oil equivalence
MODERATE
What would change this: Multiple large PK studies showing systematic bioavailability inferiority vs fish oil. |
Bailey et al. 2025 (N=74). GMR 112% [94-132%] — non-inferior to fish oil. | Confirmed — legitimate sustainable alternative |
Fish oil genuinely lowers triglycerides and reduces muscle soreness, but most people are buying the wrong product, taking the wrong dose, and the ones hoping for heart protection are largely out of luck unless they're already high-risk and using pharmaceutical-grade pure EPA.
§4 — The Claims
Fish oil is marketed as a universal health supplement — a daily pill that protects your heart, sharpens your brain, fights inflammation, lifts your mood, and keeps your joints moving. The pitch is simple: modern Western diets are overloaded with inflammatory omega-6 fats and dangerously short on anti-inflammatory omega-3s, and supplementing EPA and DHA corrects this imbalance.
The cardiovascular claim is the biggest: fish oil is positioned as a natural alternative to statins, a way to protect your heart without drugs. Millions of people take a 1,000mg softgel daily specifically because they've been told it prevents heart attacks and strokes.
Meanwhile, the mental health claim has surged — omega-3s are routinely recommended as an adjunct for depression, anxiety, and cognitive protection with age. The athletic community uses fish oil for recovery. And the sustainable-living community has embraced algal oil as a vegan-friendly equivalent.
§6 — Mechanism
EPA and DHA are long-chain polyunsaturated fatty acids that physically incorporate into your cell membranes. Because of their multi-kinked structure, they increase membrane fluidity and displace arachidonic acid — the raw material for inflammatory signalling. When EPA and DHA sit in your membranes, the enzymes that produce inflammatory molecules (COX and LOX) produce weaker, less inflammatory versions instead.
EPA converts into Resolvin E1 — a molecule that actively resolves inflammation rather than just blocking it. It stops white blood cell recruitment and activates macrophages to clear debris. DHA produces a parallel family (D-series resolvins, protectins, maresins) concentrated in brain and nerve tissue. This is a genuinely new understanding of inflammation biology.
EPA and DHA suppress SREBP-1c (the transcription factor that tells your liver to make more fat from scratch) and simultaneously activate PPAR-α (the switch that accelerates fat burning in the liver). Less fat being made, more fat being burned — triglycerides fall. This happens at 2g/day and scales dose-dependently up to about 4g/day.
EPA → E-series resolvins that cross the blood-brain barrier and modulate neuroinflammation. DHA does not follow this pathway at clinically relevant supplemental doses. This is why formulation specificity (≥60% EPA) is not a marketing preference — it's a mechanistic requirement for the antidepressant signal.
§8 — Translational Barriers
§9 — The Protocol
| Population | Dose | Timing | Form | Source |
|---|---|---|---|---|
| General adult (maintenance) | 1-2g EPA+DHA/day | With largest meal | Natural TG or rTG | AHRQ review |
| High triglycerides (therapeutic) | 2-4g EPA+DHA/day | With high-fat meal | Prescription EE or rTG | AHRQ; REDUCE-IT protocol |
| Depression support | 1-2g EPA+DHA/day (≥60% EPA) | With meal | EPA-dominant formula | Liao et al. 2019 |
| CVD high-risk (statin + hypertriglyceridemia) | 4g/day EPA-only | With meal | Icosapent ethyl (Rx) | REDUCE-IT |
| Athletic recovery / DOMS | 1-6g EPA+DHA/day | Daily, with food | TG or rTG | ISSN 2025 |
| Vegan / vegetarian | 1-2g EPA+DHA/day | With meal | Algal oil (Nannochloropsis) | Bailey 2025 |
| ⚠ AFib history (paroxysmal) | AVOID >1g/day | — | — | Gencer 2021 |
Ethyl Ester forms: Always take with a high-fat meal (≥40g fat). Without it, bioavailability drops 30-50%. This includes most concentrated OTC fish oils.
Natural TG and rTG forms: Minimal food requirement — a small amount of fat is sufficient. More forgiving than EE forms.
Algal oil — species matters: Nannochloropsis-derived algal oil stores EPA in high-bioavailability glycolipid matrices. Check the label for species designation.
Quality is not optional: Look for IFOS 5-star or GOED certification. Rancid fish oil (strong fishy smell, rancid taste) may be actively harmful, not just ineffective.
Read the label correctly: "1,000mg Fish Oil" ≠ 1,000mg EPA+DHA. A standard softgel contains ~300mg active (180mg EPA / 120mg DHA). Achieving 2g/day requires 7 standard capsules — this is why concentrated forms matter.
§10 — Safety
Gencer et al. 2021 (N=81,210, 7 RCTs): 25% increased AFib risk (HR 1.25). Dose-dependent: ≤1g/day = +12% risk; >1g/day = +49-51% risk. This is a relative contraindication for anyone with paroxysmal AFib history — risk-benefit must be assessed by a prescriber.
Additive antiplatelet effect — prolonged bleeding time. Monitor INR; use caution >3g/day. EFSA considers ≤5g/day safe overall, but clinical warfarin monitoring is advised at higher doses.
Synergistic antithrombotic — minor bleeding risk increase. Generally safe (co-administered in the ASCEND trial); inform prescriber. Low/Moderate concern.
Additive/synergistic — addresses residual hypertriglyceridemia unaffected by statins. Optimal combination for TG-lowering goals. No safety concern.
Synergistic — omega-3 reduces osteoclast activity, augmenting bone mineralization. Stack intentionally for bone health goals.
Synergistic in postmenopausal women — compound reductions in bone turnover and joint inflammation confirmed. Relevant for postmenopausal clients on HRT.
| Side Effect | Incidence | Dose-Related? | Management |
|---|---|---|---|
| Fishy burps / reflux | Common (~10-15%) | Yes | Take with meals; enteric-coated or rTG forms; store in freezer |
| Loose stools / GI discomfort | Occasional | Yes — high doses (>3g/day) | Divide dose across meals |
| LDL-C increase | Dose-related | Yes | DHA-containing EE forms raise LDL-C 2-5%. EPA-only forms do not. Consider EPA-only if LDL elevation is a concern. |
| Atrial fibrillation | Dose-dependent | Yes — +12% ≤1g/day, +49-51% >1g/day | Screen for AFib history before recommending high-dose protocols |
EFSA Tolerable Upper Intake Level: 5g/day combined EPA+DHA (2012 — no increased bleeding or immune risk in adults). DHA-alone: 1g/day supplemental (conservative 2026 guidance). Practical ceiling: 4g/day for therapeutic protocols — no additional benefit established beyond this for most endpoints.
§11 — Population Stratification
Dose-dependent TG reduction at 2-4g/day. Largest absolute reductions at higher baseline TG. Use concentrated rTG or EE form with fat.
Icosapent ethyl (4g/day, EPA-only, Rx) provides genuine MACE reduction in this specific population. Requires prescription — not OTC fish oil.
EPA-dominant formulas (≥60% EPA, 1-2g/day) provide meaningful adjunct benefit (SMD = -1.03). DHA-dominant formulas don't work. Formulation choice is critical.
1-6g/day reduces DOMS, improves RBC deformability, supports endurance capacity. No hypertrophic benefit. ISSN Tier 1 evidence.
Synergistic bone-protective and anti-inflammatory effects confirmed mechanistically. Limited specific RCT data — mechanistically supported.
Anti-inflammatory benefit most pronounced at ≥2-3g/day in high-baseline-inflammation individuals. General population effect weak.
Algal oil is non-inferior to fish oil and is the only direct EPA+DHA source for plant-based diets. ALA conversion from flaxseed is insufficient for most people.
| Form | Effective Daily Dose | Monthly Cost | Food Alternative |
|---|---|---|---|
| Natural TG (standard retail) | 7 capsules for 2g EPA+DHA | £15–25/mo | Salmon: ~3g EPA+DHA per 100g fillet. 3 servings/week ≈ 1.3g/day — sufficient for maintenance |
| rTG (concentrated OTC) | 2-3 capsules for 2g EPA+DHA | £25–40/mo | |
| Ethyl Ester (OTC concentrated) | 2-3 capsules WITH high-fat meal | £20–35/mo | — |
| Algal oil | 2-3 capsules for 1-2g EPA+DHA | £30–45/mo | No plant food source for direct EPA+DHA |
§12 — Conviction
§13 — References
§7 — Where Studies Disagree
REDUCE-IT (Bhatt et al. 2018, N=8,179)
4g/day icosapent ethyl (EPA-only) reduces MACE by 25% (HR 0.75) in high-risk statin-treated patients with elevated triglycerides.
STRENGTH (Nicholls et al. 2020, N=13,078)
4g/day EPA+DHA completely neutral (HR 0.99). Trial stopped early due to futility.
Why they disagree: REDUCE-IT used mineral oil as placebo — this raised LDL-C and CRP in the control group, explaining an estimated 7-12% of the apparent benefit. The remaining ~13% may be a genuine EPA-specific plaque-stabilizing effect. EPA-only may stabilize vulnerable plaques in a way that DHA interrupts. The debate is unresolved — no inert-placebo definitive trial exists.
ASCEND (Bowman 2018, N=15,480) + ORIGIN (Bosch 2012, N=12,536)
1g/day EPA+DHA: no cardiovascular benefit (HR 0.97-0.98) in T2DM and dysglycemia patients.
REDUCE-IT (high-dose EPA group)
4g/day EPA-only: significant hard event reduction in high-risk patients.
Why they disagree: Blood EPA enrichment thresholds for hard plaque effects require pharmacologic doses that OTC consumers never reach. The 1g standard dose is insufficient — even if efficacious, the effect size at 1g is too small for clinical significance in adequately powered trials.
EPA ≥60% formulas (Liao et al. 2019 meta-analysis)
Significant antidepressant benefit at 1-2g/day: SMD = -1.03 (p=0.03) across 26 RCTs, N=2,160.
DHA-dominant or low-EPA formulas
Consistently fail to separate from placebo in meta-analyses. No meaningful effect size.
Why they disagree: EPA → E-series resolvins that cross the blood-brain barrier and modulate neuroinflammation. DHA does not follow this pathway at clinically relevant supplemental doses. This is a mechanistic difference, not statistical noise — formulation choice is everything for the depression signal.
Current direction: The cardiovascular evidence is fracturing. OTC fish oil for heart protection is increasingly difficult to justify in general populations. The TG-lowering, anti-inflammatory, and athletic recovery applications remain robust across the debate lines.
How strong is the evidence for the claims in this review? Higher = more confidence the claims are supported. This does not measure how large the effect is or how important it is compared with other levers.
Evidence-scored dosing, timing, forms, and who should skip it. One page, no fluff.
Get the protocolConviction-scored verdicts on supplements, nutrition, training, physio, and recovery.